Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab in Pediatric and Young Adult New Onset T1DM
NCT04129528Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of iscalimab in type 1 diabetes mellitus (T1D), sponsored by Novartis. Started Nov 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04129528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129528.